Michael Schaeffer
Net worth: - $ as of 2026-05-30
Net worth: - $ as of 2026-05-30
Dr. Michael Schaeffer is an Executive Director & Chief Business Officer at Vivoryon Therapeutics NV.
He is on the Board of Directors at Vivoryon Therapeutics NV.
Dr. Schaeffer was previously employed as a Chief Executive Officer & Managing Director by Crelux GmbH and a Chief Executive Officer & Managing Director by SiREEN AG.
He received his doctorate degree from Ludwig-Maximilians-Universität München.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-16 | 0 ( -.--% ) | - $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Director/Board Member | - |
| Companies | Position | End |
|---|---|---|
Crelux GmbH
Crelux GmbH BiotechnologyHealth Technology Provides drug discovery services | Chief Executive Officer | 2016-02-29 |
SiREEN AG
SiREEN AG Miscellaneous Commercial ServicesCommercial Services Researches and discovers drugs specializing in diseases such as colon cancer and immune tolerance | Chief Executive Officer | 2003-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
SiREEN AG
SiREEN AG Miscellaneous Commercial ServicesCommercial Services Researches and discovers drugs specializing in diseases such as colon cancer and immune tolerance | Commercial Services |
Ludwig-Maximilians-Universität München
Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
Crelux GmbH
Crelux GmbH BiotechnologyHealth Technology Provides drug discovery services | Health Technology |
Select your edition
All financial news and data tailored to specific country editions